Group One Trading’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-92,379
| Closed | -$281K | – | 8582 |
|
|
2024
Q4 | $281K | Buy |
+92,379
| New | +$402K | ﹤0.01% | 3644 |
|
|
2024
Q1 | – | Sell |
-157,445
| Closed | -$932K | – | 8135 |
|
|
2023
Q4 | $1.38M | Buy |
157,445
+73,327
| +87% | +$601K | ﹤0.01% | 2158 |
|
|
2023
Q3 | $965K | Buy |
84,118
+75,341
| +858% | +$1.45M | ﹤0.01% | 2303 |
|
|
2023
Q2 | $222K | Sell |
8,777
-19,016
| -68% | -$592K | ﹤0.01% | 3826 |
|
|
2023
Q1 | $895K | Sell |
27,793
-92,297
| -77% | -$2.88M | ﹤0.01% | 2230 |
|
|
2022
Q4 | $2.22M | Buy |
+120,090
| New | +$2.75M | 0.01% | 1743 |
|
|
2022
Q3 | – | Sell |
-4,637
| Closed | -$94.1K | – | 8406 |
|
|
2022
Q2 | $64K | Sell |
4,637
-15,693
| -77% | -$242K | ﹤0.01% | 5364 |
|
|
2022
Q1 | $396K | Buy |
+20,330
| New | +$308K | ﹤0.01% | 4064 |
|
|
2021
Q4 | – | Sell |
-316
| Closed | -$5.27K | – | 8967 |
|
|
2021
Q3 | $9K | Sell |
316
-7,722
| -96% | -$220K | ﹤0.01% | 7568 |
|
|
2021
Q2 | $238K | Buy |
8,038
+1,551
| +24% | +$44.7K | ﹤0.01% | 5043 |
|
|
2021
Q1 | $181K | Sell |
6,487
-5,500
| -46% | -$152K | ﹤0.01% | 5123 |
|
|
2020
Q4 | $340K | Sell |
11,987
-534
| -4% | -$13.8K | ﹤0.01% | 3619 |
|
|
2020
Q3 | $315K | Buy |
12,521
+11,832
| +1,717% | +$310K | ﹤0.01% | 3279 |
|
|
2020
Q2 | $17K | Buy |
689
+623
| +944% | +$12.3K | ﹤0.01% | 4903 |
|
|
2020
Q1 | $1K | Sell |
66
-7,409
| -99% | -$153K | ﹤0.01% | 5125 |
|
|
2019
Q4 | $121K | Buy |
+7,475
| New | +$116K | ﹤0.01% | 3516 |
|
|
2019
Q3 | – | Sell |
-199
| Closed | -$2.44K | – | 5649 |
|
|
2019
Q2 | $3K | Hold |
199
| – | – | ﹤0.01% | 4720 |
|
|
2019
Q1 | $3K | Buy |
+199
| New | +$3.45K | ﹤0.01% | 4541 |
|
|
2018
Q2 | – | Sell |
-12
| Closed | -$361 | – | 5557 |
|
|
2018
Q1 | $0 | Sell |
12
-186
| -94% | -$5.99K | ﹤0.01% | 5392 |
|
|
2017
Q4 | $7K | Sell |
198
-802
| -80% | -$23K | ﹤0.01% | 4487 |
|
|
2017
Q3 | $28K | Buy |
+1,000
| New | +$24.2K | ﹤0.01% | 3917 |
|
|
2017
Q1 | – | Sell |
-801
| Closed | -$16.5K | – | 5078 |
|
|
2016
Q4 | $17K | Sell |
801
-1,000
| -56% | -$16.7K | ﹤0.01% | 3768 |
|
|
2016
Q3 | $29K | Buy |
1,801
+380
| +27% | +$5.52K | ﹤0.01% | 3636 |
|
|
2016
Q2 | $19K | Sell |
1,421
-2,800
| -66% | -$49.5K | ﹤0.01% | 3824 |
|
|
2016
Q1 | $74K | Sell |
4,221
-3,100
| -42% | -$63.1K | ﹤0.01% | 3026 |
|
|
2015
Q4 | $250K | Buy |
7,321
+6,621
| +946% | +$230K | ﹤0.01% | 2327 |
|
|
2015
Q3 | $21K | Buy |
+700
| New | +$21.3K | ﹤0.01% | 4018 |
|
|
2015
Q2 | – | Sell |
-2,300
| Closed | -$59.1K | – | 5236 |
|
|
2015
Q1 | $48K | Buy |
+2,300
| New | +$39.7K | ﹤0.01% | 3388 |
|
Other funds holding RVNC
Group One Trading's RVNC Position: Q1 2025 in Review
Group One Trading sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 92,379 shares — an estimated $281K sold.
Group One Trading first reported a position in RVNC in Q1 2015 and held it in 28 quarters. The position peaked at $2.22M in Q4 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Group One Trading reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Group One Trading sold 92,379 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $281K.
- Group One Trading first reported a position in Revance Therapeutics, Inc. in Q1 2015 and held it in 28 quarters.
- Group One Trading's Revance Therapeutics, Inc. position peaked at $2.22M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Group One Trading's 13F filing for Q1 2025, filed 14 May 2025.